Clinical calculator summary
New Magee Equation 1 (2013)
Clinical calculator summary
New Magee Equation 1 (2013)
A linear-regression pathology estimate, not an actual genomic-assay result.
Evidence-based context for fast calculator use
- Purpose:
- Reproduce the source equation and historical estimated category without treatment or testing advice.
- Population:
- Primary invasive ER-positive, pathologically node-negative breast carcinoma with untreated complete surgical pathology.
- Factors:
- Nottingham score, ER/PR H-scores, source-era HER2 category, Ki-67, invasive size
- Reference:
- Klein et al. Modern Pathology 2013;26:658-664. doi:10.1038/modpathol.2013.36.
New Magee Equation 1 (2013 pathology-based estimated recurrence score)
Confirm all listed conditions before entering the six pathology values.
Clinical Context & Background
15.31385 + 1.4055×Nottingham - 0.01924×ER H-score - 0.02925×PR H-score + HER2 coefficient + 0.78677×size(cm) + 0.13269×Ki-67Reference Data
| Raw unrounded New Magee Equation 1 estimate | Historical estimated category |
|---|---|
| <18 | Low |
| 18 through 30 inclusive | Intermediate |
| >30 | High |
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
When To Use
- Use New Magee Equation 1 (2013 pathology-based estimated recurrence score) when full-precision New Magee Equation 1 estimate from complete source-compatible surgical pathology; explicitly not an actual Oncotype DX result.
- Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.
How To Interpret
- Interpret the displayed result using the calculator-specific formula and reference table, spanning <18 through >30.
- A boundary result should prompt input verification and clinical review rather than false precision.
What To Do Next
- Integrate the result with invasive versus in-situ status, stage, receptor biology, treatment timing, genomic testing, comorbidity, and patient goals.
- Document the inputs, result, timing, and clinical context so the assessment can be reproduced.
Limitations
- Do not interchange screening-risk, DCIS, invasive prognosis, genomic, and post-neoadjuvant tools.
- The result supports clinician judgment and does not independently determine treatment.
Validated Population
patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment
How to apply this result
For a representative case, verify Magee Equation 1 applicability, Nottingham histologic score, ER H-score, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.
Calculation verification history
Verified
Calculation verification history
Verified: Production browser revalidation
- Three source-backed cases passed through visible production controls at estimates 4.98, 20.54, and 68.55.
- Low, Intermediate, and High estimated categories rendered across zero-valued pathology inputs and representative profiles.
- No unexpected N/A, literal undefined value, stale control, unsupported gauge, or browser-console error was observed.
Case-level evidence is retained in validation/browser-revalidation/magee-breast-2026-08-03.json.
: Not-applicable receipt corrected and browser-revalidated locally
- A source-incompatible or uncertain population selection now shows a Magee-specific estimate-not-assigned receipt instead of generic missing-or-invalid-input wording.
- Ten visible-browser cases passed across 11 submissions, covering all three estimated categories, raw 18 and 30 threshold transitions, HER2 branches, applicability, and reset/repeat.
- The New Magee Equation 1 coefficients, full-precision estimate, and raw category mapping remain unchanged and pass 12,288/12,288 independent assertions.
Case-level local remediation evidence is retained in validation/browser-production/magee-breast.local-remediation.json; the original production finding remains retained separately.
: Production browser validation
- Ten source-backed cases were exercised on the public production route through visible browser controls; 9/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
- Overall browser status: failed-ui-and-console. medium: The correct Not applicable result also displays the generic trace Required input is missing or invalid despite a complete intentional not-confirmed applicability choice. | medium: Production emitted minified React error #418 during the route load.
- Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.
Case-level production evidence is retained in validation/browser-production/magee-breast.json.
: Model identity corrected
- Locked the route to New Magee Equation 1 (2013) and separated it from the original equation, equations 2/3, averages, decision algorithms, and the actual proprietary assay.
- Removed TAILORx/RxPONDER and genomic-testing substitution framing.
: Calculation and inputs corrected
- Restored the exact published coefficients, HER2 terms, historical category boundaries, full-precision classification, two-decimal display, and unclamped regression output.
- Replaced favorable defaults and Number coercion with an exact 12-key surgical-pathology and source-applicability contract.
: Full validation completed
- 12288/12288 deterministic assertions passed, including all 5376 lattice combinations against a separately encoded literal oracle.
- This is software implementation verification, not prospective or independent clinical validation, assay equivalence, or treatment guidance.
: Public form simplified
- Combined six source-population and pathology-context questions into one early applicability confirmation.
- Preserved all six equation determinants: Nottingham score, ER H-score, PR H-score, source-era HER2 category, Ki-67, and invasive size.
- The compact adapter projects confirmed applicability into the unchanged strict 12-key engine; declined or uncertain applicability stops before pathology entry.
Public-form parity is covered by the calculator entry-burden audit; the verified equation, coefficients, thresholds, and report remain unchanged.
Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.
Related Tools
Frequently Asked Questions
Is this an Oncotype DX result?
No. It is a pathology-based regression estimate and cannot reproduce the proprietary assay, recurrence probability, confidence intervals, or treatment benefit.
How is HER2 entered?
Enter the externally established source-era category. The route does not reinterpret current HER2 testing or derive a category from raw IHC/FISH data.
Evidence-based oncology decision support. Verify with clinical guidelines.